WO2022020542A1 - Treatment and prevention of conditions associated with respiratory diseases - Google Patents
Treatment and prevention of conditions associated with respiratory diseases Download PDFInfo
- Publication number
- WO2022020542A1 WO2022020542A1 PCT/US2021/042684 US2021042684W WO2022020542A1 WO 2022020542 A1 WO2022020542 A1 WO 2022020542A1 US 2021042684 W US2021042684 W US 2021042684W WO 2022020542 A1 WO2022020542 A1 WO 2022020542A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- antigen
- subject
- administration
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- a composition for use in preventing a disease in an animal comprises: a lipid-based particle comprising an antigen and a modulator, wherein the modulator is a pattern recognition receptor agonist.
- a composition for use in treating a disease in a subject comprises: a lipid-based particle comprising an antigen and a modulator, wherein the modulator is a pattern recognition receptor agonist.
- the lipid-based particle is a liposome.
- the lipid-based particle comprises DPPG (l,2-dipalmitoyl-sn-glycero-3- phospho-(l'-rac-glycerol)), DPPE (l,2-bis(diphenylphosphino)ethane), DPPC (1,2-dipalmitoyl-sn- glycero-3-phosphocholine), DPPE-PEG2000 (l,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine- N-[methoxy (polyethylene glycol)-2000]), cholesterol, or a combination thereof.
- the lipid-based particle comprises DPPC, DPPG, cholesterol, and DPPE-PEG2000.
- the antigen comprises a killed pathogen or a portion thereof. In some cases, the antigen comprises a peptide or a protein of a pathogen. In some cases, the antigen comprises a spike protein or portion thereof. In some cases, the antigen comprises a nucleocapsid protein or portion thereof. In some cases, the antigen comprises a chimeric protein. In some cases, the antigen is trimeric. In some cases, the antigen comprises an attenuated or killed version of a tumor cell. In some cases, the tumor cell is associated with a cancer. In some cases, the antigen comprises a peptide or a protein associated with a cancer cell.
- the modulator is capable of activating or inhibiting of the stimulator of interferon genes (STING) pathway in the subject.
- the modulator is an agonist of the STING pathway.
- the modulator is selected from the group consisting of bis-(3',5')-cyclic dimeric guanosine monophosphate (c-di-GMP), cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), amidobenzimidazole, derivatives of amidobenzimidazole, nucleotide modulators, plasmid DNA modulators or a combination thereof.
- the modulator is an antagonist of the STING pathway.
- the disease comprises an infection caused by a pathogen.
- the pathogen is a respiratory pathogen.
- the respiratory pathogen is a vims.
- the virus is selected from an influenza virus, a parainfluenza vims, an adenovirus, an enterovims, a coronavims, a respiratory syncytial vims, a rhinovims, a DNA vims, an RNA vims, or a combination thereof.
- the influenza vims is an influenza A vims or an influenza B vims.
- the vims is a respiratory syncytial vims.
- the vims is a coronavims.
- the disease is a respiratory disease.
- the disease comprises a cancer.
- the cancer is selected from tracheal cancer, lung cancer, bronchial cancer, epithelial cancer, blood cancer, breast cancer, melanoma, ovarian cancer, gynecological cancer, leukemias, lymphomas, prostate cancer, bladder cancer, colon cancer, gliomas, sarcomas, glioblastoma, or a combination thereof.
- the cancer is lung cancer.
- the composition is in the form of a vaccine.
- the composition is suitable for an administration mode selected from the group consisting of intravenous administration, intramuscular administration, intradermal administration, intraperitoneal administration, subcutaneous administration, spray-based administration, aerosol-based administration, in ovo administration, oral administration, intraocular administration, intratracheal administration, intranasal administration, inhalational administration, or combinations thereof.
- the composition is lyophilized.
- the composition is formulated in unit dose formulation as a monotherapy.
- the composition comprises an adjuvant.
- the composition is suitable for developing immunity in the subject against the disease.
- the composition elicits an immune response against the disease.
- the composition elicits an innate immune response in the subject against the disease.
- the innate immune response leads to the activation of interferon regulator factors (IRFs). In some cases, the innate immune response leads to the activation of nuclear factor KB (NF-KB). In some cases, the innate immune response leads to the synthesis and secretion of type-I and type-III interferons and the subsequent upregulation of IFN- stimulated genes (ISGs).
- IRFs interferon regulator factors
- NF-KB nuclear factor KB
- ISGs IFN- stimulated genes
- a method of preventing a disease in a subject comprises: administering to the subject a composition described above or herein.
- a method of treating a disease in a subject comprises: administering to the subject a composition described above or herein.
- the composition is suitable for developing immunity in the subject against the disease.
- administering the composition to the subject elicits an immune response in the subject against the disease.
- administering the composition elicits an innate immune response in the subject against the disease.
- the innate immune response leads to the activation of interferon regulator factors (IRFs) in the subject.
- the innate immune response leads to the activation of nuclear factor KB (NF-KB).
- IRFs interferon regulator factors
- the innate immune response leads to the synthesis and secretion of type-I and type-III interferons and the subsequent upregulation of IFN- stimulated genes (ISGs).
- the innate immune response leads to associated adaptive immunity.
- the disease is caused by a pathogen.
- the pathogen is a respiratory pathogen.
- the respiratory pathogen is a virus.
- the virus is selected from a severe acute respiratory syndrome coronavirus (SARS- CoV), a severe acute respiratory syndrome-related coronavirus (SARSr-CoV), a human coronavirus 229E (HCoV- 229E), a human coronavirus NL63 (HCoV-NL63), a human coronavirus OC43 (HCoV-OC43), a human coronavirus HKU1 (HCoV-HKUl), a Middle East respiratory syndrome- related coronavirus (MERS-CoV), a severe acute respiratory syndrome-related coronavirus 2 (SARS- CoV-2), a variant of SARS-CoV-2, or combinations thereof.
- the disease is a cancer.
- the cancer is selected from tracheal cancer, lung cancer, bronchial cancer, epithelial cancer, blood cancer, breast cancer, melanoma, ovarian cancer, gynecological cancer, a leukemia, a lymphoma, prostate cancer, bladder cancer, colon cancer, a glioma, a sarcoma, glioblastoma, or a combination thereof.
- the cancer is lung cancer.
- the composition is administered to the subject by intravenous administration, intramuscular administration, intradermal administration, intraperitoneal administration, subcutaneous administration, spray-based administration, aerosol-based administration, in ovo administration, oral administration, intraocular administration, intratracheal administration, intranasal administration, inhalational administration, or combinations thereof.
- the composition is administered to the subject by intranasal administration.
- the composition is administered to the subject by inhalation administration.
- the composition is administered to the subject in single dose.
- the one or more adjuvant treatments are selected from immunotherapy, virotherapy, targeted inhibition, radiotherapy, chemotherapy, or a combination thereof.
- the subject is a mammal.
- the subject is at risk of having a respiratory infection or a cancer.
- the method is used to prevent the establishment of the disease in the subject.
- the method is used to prevent progression of the disease in the subject.
- the method is used to prevent the transmission of disease to a second subject.
- FIG. 5B shows a timeline of body weight measurements for in vivo mouse subject testing with compositions described herein for treating or preventing a disease, in accordance with embodiments.
- FIG. 5C shows a timeline of body weight measurements for in vivo mouse subject testing with compositions described herein comprising a liposome, a trimeric antigen, and a STING agonist versus control treatments using a composition without the trimeric antigen or STING agonist, in accordance with embodiments.
- FIG. 5F shows assessment of humoral immune responses using antigen-based IgG ELISA analysis of bronchoalveolar lavage fluid obtained from mice on day 15 following administration of a composition described herein comprising a liposome, a trimeric antigen, and a STING agonist versus control treatments using a composition without the trimeric antigen or STING agonist, in accordance with embodiments.
- FIG. 5G shows time-dependent kinetics of humoral immune responses in treated mice using antibody titers of blood serum collected at day 7, day 15, day 21, and day 24 after administration of a composition described herein comprising a trimeric antigen and STING agonist, in accordance with embodiments.
- FIG. 5H shows longitudinal analysis of the data for each mouse subject presented in
- FIG. 5K shows a quantification of S-protein specific IgA levels detected in animal subjects’ serum at day 24 following treatment with a composition described herein comprising a liposome, a trimeric antigen, and a STING agonist versus control treatments using a composition without the trimeric antigen or STING agonist, in accordance with embodiments.
- FIG. 5L shows a quantification of S-protein specific IgA levels detected in bronchoalveolar lavage fluid obtained from mice treated with a composition described herein comprising a liposome, a trimeric antigen, and a STING agonist versus control treatments using compositions without the trimeric antigen or STING agonist, in accordance with embodiments.
- FIG. 5M shows ID50 levels for antibody responses determined from pseudovirus neutralization assay measurements of serum from mice treated with a composition described herein comprising a liposome, a trimeric antigen, and a STING agonist, in accordance with embodiments.
- FIG. 5N shows ID50 levels for bronchoalveolar lavage fluid antibody responses determined from pseudovirus neutralization assay measurements of bronchoalveolar lavage fluid (BALF) from animal subjects treated with a composition described herein comprising a liposome, a trimeric antigen, and a STING agonist, in accordance with embodiments.
- BALF bronchoalveolar lavage fluid
- FIG. 6B, FIG. 6C, and FIG. 6D show flow cytometry gating strategies for isolation of live cells for use in single-cell RNA sequencing (scRNA-seq) assays, in accordance with embodiments.
- cells are identified using a flow cytometry gate as shown in FIG. 6B, single cells are identified from the population of cells obtained with the gate shown in FIG. 6B by using the gate in FIG. 6C, and live single cells are obtained from the population of single cells obtained with the gate shown in FIG. 6C by using the gate in FIG. 6D.
- FIG. 7A shows a uniform manifold approximation and projection (UMAP) analysis of immune cells in the nasal-associated lymphoid tissue (NALT) of animal subjects treated with compositions described herein comprising an antigen, a liposome, and a STING agonist, in accordance with embodiments.
- FIG. 7B, FIG. 7C, FIG. 7D show violin plots of relative expressions of B-cell markers CD19, Ms4al, and CD79a, respectively, in immune cell populations obtained from animal subjects treated with compositions described herein comprising an antigen, a liposome, and a STING agonist, in accordance with embodiments.
- FIG. 7G show violin plots of relative expressions of T-cell markers CD3d, CD3e, and CD3g, respectively, in immune cell populations obtained from animal subjects treated with compositions described herein comprising an antigen, a liposome, and a STING agonist, in accordance with embodiments.
- FIG. 7H, FIG. 7-1, and FIG. 7J show violin plots of relative expressions of NK-cell markers GzmB, Ncrl, and Ccl5, respectively, in immune cell populations obtained from animal subjects treated with compositions described herein comprising an antigen, a liposome, and a STING agonist, in accordance with embodiments.
- FIG. 8A shows identification of B-cell subpopulations based on uniform manifold approximation and projection (UMAP) analysis of scRNA-seq assays performed on animal subjects treated with compositions described herein comprising an antigen, a liposome, and a STING agonist, in accordance with embodiments.
- UMAP uniform manifold approximation and projection
- FIG. 8C, FIG. 8D, FIG. 8E, FIG. 8F, FIG. 8G, and FIG. 8H show violin plots of relative expressions of CD69, CD38, CD83, CXCR4, Zfp36, and Ergl, respectively, in B-cell subpopulations obtained from animal subjects treated with compositions described herein comprising an antigen, a liposome, and a STING agonist, in accordance with embodiments.
- FIG. 9A, FIG. 9B, FIG. 9C, FIG. 9D, FIG. 9E, FIG. 9F, FIG. 9G, FIG. 9H, FIG. 9-1, FIG. 9J, FIG. 9K, FIG. 9L, and FIG. 9M show violin plots of relative expressions of CD 19, Ms4al, Ighm, Irf4, Pax5, Sec61b, Fosb, Jun, Traml, Igha, EGR3, Casp3, and Fos, respectively, in B-cell subpopulations identified using UMAP analysis using cells obtained from animal subjects treated with compositions described herein comprising an antigen, a liposome, and a STING agonist, in accordance with embodiments.
- FIG. 9A, FIG. 9B, FIG. 9C, FIG. 9D, FIG. 9E, FIG. 9F, FIG. 9G, FIG. 9H, FIG. 9-1, FIG. 9J, FIG. 9K, FIG. 9L, and FIG. 9M show violin plots of relative expressions of CD
- FIG. IOC, FIG. 10D, FIG. 10E, FIG. 10F, FIG. 10G, and FIG. 10H show violin plots of relative expressions of CD69, 116ra, CD27, Nr4al, Tcf7, and Lefl, respectively, in T-cell subpopulations obtained from animal subjects treated with compositions described herein comprising an antigen, a liposome, and a STING agonist, in accordance with embodiments.
- FIG. 12A shows a cell-cell interaction network produced using data obtained from scRNA- seq analysis of cells obtained from nasal-associated lymphoid tissues of animal subjects treated with compositions described herein comprising an antigen, a liposome, and a STING agonist, in accordance with embodiments.
- FIG. 12A shows a cell-cell interaction network produced using data obtained from scRNA- seq analysis of cells obtained from nasal-associated lymphoid tissues of animal subjects treated with compositions described herein comprising an antigen, a liposome, and a STING agonist, in accordance with embodiments.
- FIG. 13C shows IgG ELISA quantification of humoral immune responses in serum obtained from animal subjects on day 15 (“dl5”) following treatment with compositions described herein comprising a liposome, a monomeric antigen, and a STING agonist versus control treatments using a composition without the monomeric antigen or STING agonist, in accordance with embodiments.
- FIG. 13C shows IgG ELISA quantification of humoral immune responses in serum obtained from animal subjects on day 15 (“dl5”) following treatment with compositions described herein comprising a liposome, a monomeric antigen, and a STING agonist versus control treatments using a composition without the monomeric antigen or STING agonist, in accordance with embodiments.
- FIG. 13F shows that monomeric protein-specific IgA was detectable in nasal wash of two animal subjects treated with a composition described herein comprising a liposome, a monomeric antigen, and a STING agonist, in accordance with embodiments (limit of detection (LoD) is shown with a dotted line; horizontal line represents the data point mean).
- FIG. 16 shows a schematic of method steps comprising administration of compositions described herein comprising a liposome, a nucleocapsid protein antigen, and a STING agonist to an animal subject for treating or preventing disease or administration of control compositions lacking the nucleocapsid protein antigen and the STING agonist, in accordance with embodiments [0043]
- FIG. 17 shows induction of interferon response factor (IRF) responses in THP-1 cells isolated from animal subjects at 6 hours, 12 hours, or 24 hours following treatment with compositions described herein comprising liposomes, nucleocapsid protein, and cGAMP, in accordance with embodiments.
- IRF interferon response factor
- FIG. 20A shows fluorescence emission spectra of DNA-bound DiYO-1 in the presence of the nucleocapsid protein represented in FIG. 18 at nucleocapsid concentrations of 0 mM, 0.1 mM, 0.5 mM, in accordance with embodiments.
- FIG. 20B shows fluorescence emission spectra of DNA- bound DiYO-1 in the presence of a DNA binding positive control (branched-chain polyethyleneimine (PEI)) at various molar ratios (R) of PEI nitrogen to DNA phosphate), in accordance with embodiments.
- PEI branched-chain polyethyleneimine
- FIG. 21A shows a timeline of steps for intranasal treatment or vaccination of a mouse subject and sample collection, in accordance with embodiments.
- FIG. 21B shows IgG ELISA quantification of humoral immune responses in serum obtained from animal subjects on day 27 (“D27”) following treatment with compositions described herein comprising a liposome, 10 mg nucleocapsid protein (N-protein)) antigen, and a STING agonist (“NanoSTING-NlO”) versus treatment with compositions described herein comprising a liposome, 20 mg nucleocapsid protein (N-protein)) antigen, and a STING agonist (“NanoSTING-N20”), and versus control treatments using a composition without the nucleocapsid protein antigen or STING agonist (“Control”), in accordance with embodiments.
- FIG. 21C shows IgG ELISA quantification of humoral immune responses in bronchoalveolar lavage fluid (BALF) obtained from animal subjects on day 27 (“D27”) following treatment with compositions described herein comprising a liposome,
- BALF bronchoalveolar lavage fluid
- FIG. 22 shows a quantification of ELISpot analysis of interferon gamma (IFNy) and interleukin-4 (IL4) for cells obtained from spleen and lung samples after treatment with compositions described herein comprising a liposome, 10 mg nucleocapsid protein (N-protein)) antigen, and a STING agonist (“NanoSTING-NlO”) versus treatment with compositions described herein comprising a liposome, 20 mg nucleocapsid protein (N-protein)) antigen, and a STING agonist (“NanoSTING-N20”), and versus control treatments using a composition without the nucleocapsid protein antigen or STING agonist, in accordance with embodiments.
- IFNy interferon gamma
- IL4 interleukin-4
- FIG. 24A shows a flow cytometry quantification of CD137 expression in splenic cells that are also CD8-positive (CD8 + ) from animal subjects having been treated with compositions described herein comprising a liposome, 10 mg nucleocapsid protein (N-protein)) antigen, and a STING agonist (“NanoSTING-NlO”) versus treatment with compositions described herein comprising a liposome, 20 mg nucleocapsid protein (N-protein)) antigen, and a STING agonist (“NanoSTING- N20”), and versus control treatments using a composition without the nucleocapsid protein antigen or STING agonist, in accordance with embodiments.
- CD8 + CD8-positive
- FIG. 25A shows a flow cytometry quantification of granzyme B (GrB) expression in splenic cells that are also CD8-positive (CD8 + ) from animal subjects having been treated with compositions described herein comprising a liposome, 10 mg nucleocapsid protein (N-protein)) antigen, and a
- FIG. 29 shows nucleocapsid protein-reactive IgG ELISA quantifications of humoral immune responses in serum obtained from animal subjects at day 7 (“d7”), day 14 (“dl4”), day 21 (“d21”), and day 27 (“d27”) following treatment with compositions described herein comprising a liposome, 10 mg nucleocapsid protein (N-protein)) antigen, and a STING agonist (“NanoSTING-NlO”) and treatment with compositions described herein comprising a liposome, 20 mg nucleocapsid protein (N-protein)) antigen, and a STING agonist (“NanoSTING-N20”) , in accordance with embodiments.
- FIG. 29 shows nucleocapsid protein-reactive IgG ELISA quantifications of humoral immune responses in serum obtained from animal subjects at day 7 (“d7”), day 14 (“dl4”), day 21 (“d21”), and day 27 (“d27”) following treatment with compositions described herein
- FIG. 30A shows ELISA quantification of IgG reactivity to alpha (“a”), beta (“b”), and gamma (“g”) variants of a chimeric spike protein trimer, or to the receptor binding domain of the alpha or gamma variants, using serum samples obtained from animal subjects at day 28 following treatment with compositions described herein comprising a liposome, the chimeric spike protein trimer antigen, and a STING agonist (“NanoSTING-ChimS”) versus treatment with control compositions described herein comprising a liposome lacking the chimeric spike protein trimer antigen and the STING agonist, in accordance with embodiments.
- FIG. 31B shows interferon gamma (IFNy) responses, as quantified using ELISpot assay, in lung samples of animal subjects treated with NanoSTING-ChimS composition described herein comprising a liposome, a gamma variant chimeric spike protein trimer antigen, and a STING agonist versus treatment with a control composition described herein comprising a liposome lacking a chimeric spike protein, in accordance with embodiments. Bars and columns show median values, significance was asserted at *p ⁇ 0.05; **p ⁇ 0.01 using a Mann-Whitney test.
- IFNy interferon gamma
- FIG. 34A and FIG. 34C show distributions of liposomal particle sizes measured by dynamic light scattering (DLS) after composition storage at 4 °C, in accordance with embodiments.
- DLS dynamic light scattering
- FIG. 35A and FIG. 35B show distributions of liposomal particle sizes measured by dynamic light scattering (DLS) where the antigen is stored in solution (FIG. 35A) or as a lyophilized solid (FIG. 35B), in accordance with embodiments.
- DLS dynamic light scattering
- compositions described herein can comprise a lipid-based liposome particle, modulator (such as a pattern recognition receptor agonist, e.g., a STING agonist), and an application-specific antigen (such as a coronavims spike protein (“S- protein”), a nucleocapsid protein (“N-protein”), or a chimeric antigen protein) associated with the liposome particle.
- modulator such as a pattern recognition receptor agonist, e.g., a STING agonist
- an application-specific antigen such as a coronavims spike protein (“S- protein”), a nucleocapsid protein (“N-protein”), or a chimeric antigen protein
- association of an application-specific antigen with (e.g., an outer surface of) a liposome particle encapsulating a modulator payload can significantly increase the targeting and/or delivery of the modulator payload to a target tissue of interest (e.g., an intranasal compartment and/or a lung compartment of a subject).
- a target tissue of interest e.g., an intranasal compartment and/or a lung compartment of a subject.
- association e.g., direct association, such as through incorporation into the liposomal membrane or through coupling to the liposomal membrane surface
- association e.g., direct association, such as through incorporation into the liposomal membrane or through coupling to the liposomal membrane surface
- association e.g., direct association, such as through incorporation into the liposomal membrane or through coupling to the liposomal membrane surface
- association e.g., direct association, such as through incorporation into the liposomal membrane or through coupling to the liposomal membrane surface
- association of an application- specific antigen with a liposome particle may increase the efficacy of the composition in preventing and/or treating a disease or pathological condition in a subject, for example, by spatially concentrating an antigen and a modulator of the composition (e.g., at a target tissue).
- a composition for preventing or treating a disease or pathological condition in a subject can comprise a delivery vehicle (e.g., a particle).
- a delivery vehicle of a composition useful in preventing or treating a disease or pathological condition in a subject can be a particle, such as a lipid-based particle.
- a composition useful in preventing or treating a disease or pathological condition in a subject can comprise a lipid-based particle, such as a liposome (e.g., having a membrane with an outer surface and an interior space).
- the composition comprises one or more modulators (e.g., one or more types of modulators).
- a modulator can comprise a small molecule, a protein or fragment thereof, and/or a polynucleotide or fragment thereof.
- a modulator e.g., a STING agonist
- combination of modulators can be selected for use in a composition described herein for its ability to induce activation or inhibition of a signaling pathway and/or a systemic response pathway (e.g., the stimulator of interferon genes (STING) pathway) in a subject.
- a composition useful in preventing or treating a disease or pathological condition in a subject can comprise one or more antigens.
- an antigen of a composition described herein can elicit an immune response in a subject, which may be useful in preventing or abrogating a disease (e.g., a respiratory disease) or pathological condition (e.g., cancer) in the subject.
- a composition for preventing or treating a disease or a pathological condition in a subject can comprise a modulator (e.g., a STING agonist, such as cGAMP) encapsulated within a particle (e.g., a liposome) wherein an antigen is associated with the liposome or a portion thereof (e.g., via incorporation into the liposomal membrane).
- a modulator e.g., a STING agonist, such as cGAMP
- a particle e.g., a lipid-based particle can be zwitterionic.
- a particle e.g., a lipid-based particle or a portion thereof can have a net zero charge.
- a particle e.g., a lipid-based particle or a portion thereof can be uncharged.
- a particle (e.g., liposome) of a composition described herein can comprise dipalmitoylphosphatidylcholine, dipalymitoylphosphatidylglycerol, l,2-bis(diphenylphosphino)ethane (DPPE), cholesterol, or a combination thereof.
- DPPE diphenylphosphino
- a particle can comprise DPPC, DPPG, cholesterol, and DPPE-PEG2000.
- a particle can be composed of a molar ratio of 10:1:1:1 of DPPC, DPPG, cholesterol, and DPPE- PEG2000, respectively.
- a particle can be composed of a molar ratio of 20:1:1:1 of DPPC, DPPG, cholesterol, and DPPE-PEG2000, respectively.
- a particle can be composed of a molar ratio of 5: 1:1:1 of DPPC, DPPG, cholesterol, and DPPE-PEG2000, respectively.
- a particle can be composed of a molar ratio of 10:2: 1: 1 of DPPC, DPPG, cholesterol, and DPPE-PEG2000, respectively. In some cases, a particle can be composed of a molar ratio of 10:1:2:1 of DPPC, DPPG, cholesterol, and DPPE-PEG2000, respectively. In some cases, a particle can be composed of a molar ratio of 10:1:1:2 of DPPC, DPPG, cholesterol, and DPPE- PEG2000, respectively. In some cases, a particle can be composed of a molar ratio of 10:2:2:1 of DPPC, DPPG, cholesterol, and DPPE-PEG2000, respectively.
- a particle can be composed of a molar ratio of 10:1:2:2 of DPPC, DPPG, cholesterol, and DPPE-PEG2000, respectively. In some cases, a particle can be composed of a molar ratio of 10:2: 1:2 of DPPC, DPPG, cholesterol, and DPPE-PEG2000, respectively.
- a molar ratio of a first molecule comprising a particle (e.g., a lipid-based particle) to a second molecule comprising the particle can be from 1:100 to 1:1, from 1:50 to 1:2, from 1:25 to 1:3, from 1:10 to 1:5, from 1:50 to 1:1, from 1:25 to 1:1, from 1:10 to 1:1, from 1:5 to 1:1, from 1:3 to 1:1, from 1:25 to 1:10, from 1:50 to 1:25, from 1:100 to 1:50, or greater than 1:100.
- a first molecule comprising a particle (e.g., a lipid-based particle) of a composition described herein can be dipalmitoylphosphatidylcholine, dipalymitoylphosphatidylglycerol, 1 ,2- bis(diphenylphosphino)ethane (DPPE), cholesterol, or a combination thereof.
- DPPE diphenylphosphino
- a particle can have an outer diameter of 1 nanometer to 500 nanometers, 1 nanometer to 750 nanometers, or 1 nanometer to 1,000 nanometers. In some cases, a particle can have an outer diameter of 1 nanometer to 10 nanometers, 1 nanometer to 15 nanometers, 1 nanometer to 20 nanometers, 1 nanometer to 30 nanometers, 1 nanometer to 50 nanometers, 1 nanometer to 75 nanometers, 1 nanometer to 100 nanometers, 1 nanometer to 150 nanometers, 1 nanometer to 200 nanometers, 1 nanometer to 250 nanometers, 1 nanometer to 300 nanometers, 1 nanometer to 400 nanometers, 1 nanometer to 500 nanometers, 10 nanometers to 15 nanometers, 10 nanometers to 20 nanometers, 10 nanometers to 30 nanometers, 10 nanometers to 50 nanometers, 10 nanometers to 75 nanometers, 10 nanometers to 100 nanometers, 10 nanometers to 150 nanometers, 10 nanometers to 200 nanometers, 10 nanometer
- a particle can have an outer diameter of at most 1 nanometer, 10 nanometers, 15 nanometers, 20 nanometers, 30 nanometers, 50 nanometers, 75 nanometers, 100 nanometers, 150 nanometers, 200 nanometers, 250 nanometers, 300 nanometers, 400 nanometers, 500 nanometers, 750 nanometers, or 1,000 nanometers.
- one or more antigens of the present disclosure can be associated with an outer surface of a (e.g., lipid-based) particle of this disclosure.
- one or more modulators (e.g., including a STING modulator) of the present disclosure can be encapsulated within the particle.
- one or more antigens of the present disclosure can be associated with an outer surface of a (e.g., lipid-based) particle of this disclosure while one or more modulators (e.g., including a STING modulator) of the present disclosure are encapsulated within the particle.
- one or more modulators can be associated with an outer surface of a (e.g., lipid-based) particle of the present disclosure while one or more antigens of the present disclosure are integrated into a membrane of the particle.
- the incorporation of both an antigen and a modulator (e.g., a STING modulator) of the present disclosure within a (e.g., lipid-based) particle can facilitate coordinated cytosolic delivery.
- An antigen of a composition described herein can include an attenuated or killed version of a pathogen, or portion thereof, that causes a disease (e.g., one or more of the pathogens described herein).
- the antigen can comprise a peptide or a protein, or portion thereof, associated with the pathogen.
- the antigen can comprise a surface protein (e.g., receptor protein), or portion thereof, of a pathogen.
- the antigen may be in the form of a polynucleotide, for example, which may be used to express a second antigen (e.g., a plasmid DNA molecule expressing a second antigen).
- an antigen can be an influenza virus antigen or portion thereof, an influenza A vims antigen or portion thereof, an influenza B virus antigen or portion thereof, a parainfluenza virus antigen or portion thereof, an adenovirus antigen or portion thereof, an enterovirus antigen or portion thereof, a coronavims antigen or portion thereof, a respiratory syncytial vims (RSV) antigen or portion thereof, a rhino vims antigen or portion thereof, a DNA vims antigen or portion thereof, an RNA vims antigen or portion thereof, or a combination thereof
- RSV respiratory syncytial vims
- an antigen of a composition of the present disclosure can be in various forms.
- the antigens can be recombinant peptides or proteins, or peptide epitopes recognized by T-cells.
- antigens of a composition disclosed herein can comprise tandem minigenes.
- the antigen can be in the form of a nucleotide expressing the antigen (e.g., a plasmid DNA molecule expressing the antigen).
- composition described herein can comprise a vaccine or therapeutic treatment (e.g., delivered intranasally) containing a liposome containing agonists of the stimulator of interferon genes (STING) pathway to enable humoral immunity, T-cell immunity, systemic immunity and/or mucosal immunity.
- a vaccine or therapeutic treatment e.g., delivered intranasally
- a liposome containing agonists of the stimulator of interferon genes (STING) pathway to enable humoral immunity, T-cell immunity, systemic immunity and/or mucosal immunity.
- RNA viruses In the context of RNA viruses, the recognition and activation of virus-specific RNA molecules can lead to the activation of interferon regulator factors (IRFs) and nuclear factor KB (NF- KB). Together, these transcriptional regulators launch broad antiviral programs, including the synthesis and secretion of type-I and type-III interferons and the subsequent upregulation of IFN- stimulated genes (ISGs).
- IRFs interferon regulator factors
- NF- KB nuclear factor KB
- the type-1 interferon response can be suppressed in pathogen infections (e.g., coronavims or other respiratory pathogens) and the balance between the ISGs and a pro-inflammatory response mediated by NF-KB can subsequently be dysregulated. Consequently, patients with advanced disease upon pathogen infection (e.g., respiratory pathogen infection) may have low interferon signaling but exaggerated tumor necrosis factor (TNF) and interleukin-6 (IL-6) secretion. Indeed, humans with autoantibodies against interferons that neutralize interferon function can be at high risk of developing advanced disease.
- pathogen infections e.g., coronavims or other respiratory pathogens
- TNF tumor necrosis factor
- IL-6 interleukin-6
- the stimulator of interferon genes (STING) pathway is a PRR that senses cyclic DNA dinucleotides and activates IRF3 and NF-KB leading to the synthesis of ISGs.
- STING interferon genes
- the sensing of double stranded RNA derived from viruses like the coronavims within the cytoplasm of human cells can be accomplished by the RIG-I like receptors, including the retinoic acid inducible gene 1 (RIG-1) and melanoma differentiation gene 5 (MDA5).
- RIG-I like receptors including the retinoic acid inducible gene 1 (RIG-1) and melanoma differentiation gene 5 (MDA5).
- RIG-I like receptors including the retinoic acid inducible gene 1 (RIG-1) and melanoma differentiation gene 5 (MDA5).
- RIG-I like receptors including the retinoic acid inducible gene 1 (RIG-1) and melanoma differentiation gene 5 (MDA5).
- RIG-I like receptors including the retinoic acid inducible gene 1 (RIG-1) and melanoma differentiation gene 5 (MDA5).
- MDA5 melanoma differentiation gene 5
- STING agonists as therapeutics can take advantage of this conserved downstream effector responses to promote a balanced activation of type I interferons, even in the context of SARS-CoV2 infection. Enabling the release of type I interferons with STING agonists independent of the RIG-1 like receptors increases the likelihood that this is not subjected to countermeasures evolved by the vims.
- the therapeutic compositions of the present disclosure can be used to treat or prevent a disease through various mechanisms of action.
- the therapeutic compositions of the present disclosure can be used to treat a disease in a subject.
- the therapeutic compositions of the present disclosure can be used to prevent a disease in a subject.
- the therapeutic compositions of the present disclosure can be used to treat and prevent a disease in a subject.
- the therapeutic compositions of the present disclosure can be used to treat or prevent a disease in a subject by developing immunity in the subject against the disease.
- a composition of the present disclosure may be administered to a subject (e.g., an animal subject) at a
- a method of the present disclosure can comprise administering to a subject a first dose comprising a composition of the present disclosure and a second dose comprising a composition of the present disclosure.
- the composition of the first dose is the same as the composition of the second dose.
- the composition of the first dose is different than the composition of the second dose.
- a method of the present disclosure can comprise administering each dose subsequent to a first dose of a plurality of doses (e.g., wherein each dose of the plurality of doses comprises one or more compositions of the present disclosure) to a subject (e.g., an animal subject) at least 6 hours, at least 12 hours, at least 24 hours, at least 36 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 14 days, or at least 28 days after administration of the previous dose.
- a subject e.g., an animal subject
- a method of the present disclosure can comprise administering each dose subsequent to a first dose of a plurality of doses (e.g., wherein each dose of the plurality of doses comprises one or more compositions of the present disclosure) to a subject (e.g., an animal subject) 6 hours, 12 hours, 24 hours, 36 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 14 days, or 28 days.
- a subject e.g., an animal subject 6 hours, 12 hours, 24 hours, 36 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 14 days, or 28 days.
- a subject may be selected for treatment with a composition disclosed herein based on a demographic risk factor, such as obesity, advanced age (e.g., 65 years old or older), immune impairment, or pregnancy.
- a subject may be selected for treatment based on a risk of infection by a pathogen or contraction of a disease (e.g., infection by a respiratory pathogen or contraction of a respiratory disease), for instance, if the subject has an occupation involving close interaction with customers, frequent interaction with at-risk populations, handling of biological samples, or close contact with potentially infected individuals.
- the pathogen can be a respiratory pathogen.
- the respiratory pathogen can be a vims.
- the vims can be an influenza vims, an influenza A vims, an influenza B vims, a parainfluenza vims, an adenovims, an enterovirus, a coronavims, a respiratory syncytial vims, a rhinovims, a DNA vims, an RNA vims, or a combination thereof.
- the final concentration of liposomal encapsulated cGAMP and encapsulation efficiency were calculated by subtracting the concentration of free drug in the filtrate (standard curve shown in FIG. 36B).
- Freshly hydrated lyophilized form of SARS-CoV-2 spike protein (“S-protein”) monomer or, alternatively, trimer was mixed with the STINGa-liposomal suspensions at room temperature for 10 min to allow the adsorption of the protein onto the liposomes.
- the formulated composition was stored at 4 °C and used for up to 2 months. For stability determination, the STING agonist-liposomal suspensions were stored at 4°C for 11 months.
- the average particle diameter, polydispersity index, and zeta potential were characterized by Litesizer 500 at room temperature.
- Dynamic light scattering (DLS) analysis showed that the mean particle diameter of NanoSTING compositions comprising a liposome and a STING agonist (“STINGa”) modulator, cGAMP, was 81 nm, with a polydispersity index of 0.21 (FIG. 33B), while the size of blank liposomes lacking STING agonist modulator or spike protein antigen was 110 nm (FIG. 33A).
- NanoSTING-Trimer a NanoSTING trimeric S-protein composition
- the NanoSTING suspension was gently mixed with the freshly rehydrated Trimeric S-protein with gentle agitation at room temperature to allow the adsorption of the protein on the liposomes.
- the adsorbed trimeric S protein displayed a mean particle diameter of 105 nm (FIG. 33C) and a mean zeta potential of -30 mV (FIG.
- DMEM Dulbecco’s modified Eagle’s medium
- the expression plasmids for SARS-CoV-2 S-protein pCAGGS containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene was obtained from BEI Resources (Manassas, VA, USA).
- a neutralizing antibody (Nab) titration assay for SARS-CoV-2 was performed as follows. ACE2-TMPRSS2 expressing 293 T cells were cultured overnight in a half area 96-well plate compatible with Nexcelom Celigo imager at a concentration of 1 xlO 4 cells per well in 100 pi of complete media. On the day of the assay, heat-inactivated serum from mice was thawed and diluted 1:20 to 1:640 in a six-point, two-fold series in serum-free DMEM.
- T-cell responses may contribute to protection independent of antibody responses
- IFNy ELISpot assay was performed using Mouse IFN-g ELISpot Basic kit (ALP), following the manufacturer’s instructions (Mabtech, VA, USA). Frozen splenocytes or lung cells were thawed and seeded on the ELISPOT plate (l x 10 5 to 3 xlO 5 cells per well) without further culturing.
- Nasal-associated lymphoid tissue was harvested at the time of euthanasia from the animals treated with NanoSTING-Trimer (“Trimer-STINGa”) and animals treated with just the spike protein trimer.
- Nasal-associated lymphoid tissue was isolated from mice after euthanasia, and red blood cells were lysed by incubating the cells in ACK lysis buffer (Thermo Fisher Scientific, Waltham, MA) for 3 minutes. NALT samples were converted into single-cell suspensions, sorted into live, single-cell populations using flow cytometry, and subjected to scRNA- seq analysis (FIG. 6A).
- a BD FACSMelody cell sorter (BD Biosciences, San Jose, CA) was used to sort live cells.
- the flow cytometry gating strategy utilized in this method is shown in FIG. 6B, FIG. 6C, and FIG. 6D.
- Each group of NALT cells was labeled separately with Sample-Tags from the BD Mouse Immune Single-Cell Multiplexing Kit (BD Biosciences, San Jose, CA), according to protocol. Then library preparation was begun with a mixture of -6000 cells (3000 cells from each group).
- Whole transcriptome was prepared using the BD Rhapsody System following the BD “mRNA Whole Transcriptome Analysis (WTA) and Sample Tag Library Preparation Protocol”.
- Nr4al Nur77 (see FIG. 10F), Tcf7 (TCF1) (see FIG. 10G), Lefl (see FIG. 10H), I17r (see FIG. 11D), Fos (see FIG. 11F), and Jun (see FIG. 11G), and also the memory markers Cd27 (see FIG. 10E) and Cd28 (see FIG. 11C).
- the prominent difference in the control and the NanoSTING-Trimer groups was an increase in the ratio of Tfh/naive CD4+ T cells (FIG. 10B).
- GC B cells and Tfh cells represented the dominant clusters in the NanoSTING-Trimer NALT.
- Tfh cells were the dominant interacting cell type and interacted strongly with the GC B cell cluster (FIG. 12A).
- the mice genes were converted to their human counterparts and interacting protein pairs were interrogated using CellPhoneDB. Briefly, T cells and B cells were categorized by their subpopulations and group (treated or Trimer-STINGa) to 14 cell types.
- the N-protein was able to quench the fluorescence of the DNA-DiYO-1 complex in a concentration-dependent manner (FIG. 20A).
- PEI polyethylenimine
- mice Female, 7-9-week-old BAFB/c mice were purchased from Charles River Faboratories. Before administration of compositions, mice were anesthetized by intraperitoneal injection of ketamine and xylazine. Animals were treated via a single intranasal administration with one of two different concentrations of the NanoSTING-N composition comprising 20 pg of the liposome- STING adjuvant for immunization and either 10 pg or 20 pg nucleocapsid protein (NanoSTING-N 10 and NanoSTING-N20, respectively).
- the NanoSTING-N composition comprising 20 pg of the liposome- STING adjuvant for immunization and either 10 pg or 20 pg nucleocapsid protein (NanoSTING-N 10 and NanoSTING-N20, respectively).
- the plate was then blocked with PBS+1% BSA (Fisher Scientific, PA, USA) +0.1% Tween20TM (Sigma-Aldrich, MD, USA) for 2 hours at RT. After washing, we added the samples at different dilutions.
- HRP-conjugated anti-mouse IgG Jackson ImmunoResearch Laboratories, 1 in 5,000; PA, USA
- anti-mouse IgA Bethyl Laboratories, 1 : 10,000; TX, USA
- detection antibody against mouse IgA (1 : 250) from the mouse total IgA ELISA kit from Invitrogen (CA, USA).
- Example 12 Processing of Spleen and Lungs for ELISPOT and Flow Cytometry
- This example illustrates methods for harvesting and processing spleen and lung tissue from subjects treated with NanoSTING compositions.
- the lung vasculature was perfused with 5 ml of lmM EDTA in PBS without Ca 2+ or Mg 2+ injected into the right cardiac ventricle. Each lung was cut into 100-300 mm 2 pieces using a scalpel.
- Minced tissue was transferred to a tube containing 5 ml of Digestion Buffer containing Collagenase D (2mg/ml, Roche #11088858001) and DNase (0.125 mg/ml, Sigma #DN25) in 5 ml of RPMI for 1 h and 30 minutes at 37 °C in a water bath with vortexing performed after every 10 min. The remaining intact tissue was disrupted by passage (6-8 times) through a 21 -gauge needle. Cells were incubated for 90min and 500 pi of ice cold stopping Buffer (lx PBS, 0.1M EDTA) added to stop the reaction. Tissue fragments and dead cells were removed using a 40 pm disposable cell strainer (Falcon), and cells were collected after centrifugation.
- Digestion Buffer containing Collagenase D (2mg/ml, Roche #11088858001) and DNase (0.125 mg/ml, Sigma #DN25) in 5 ml of RPMI for 1 h and 30 minutes at 37 °
- CD8+ T-cell responses can complement antibody mediated responses and can offer protection independent of antibody responses.
- Activation and function of N-protein specific memory CD8+ T cells in the lung airways, lung parenchyma, and spleen was investigated in these experiments.
- Spleen and lung lymphocytes from NanoSTING-N-treated and control-treated animals were stimulated with nucleocapsid protein-peptide pool at a concentration of 1.5 pg/ml/peptide (Miltenyi Biotec; 130-126-699, Germany) at 37 °C for 16-18 hours to determine nucleocapsid protein- specific CD8+ T cell responses at 18 hours after exposure to NanoSTING-N compositions.
- about 100 nanometers (nm) represents a range of 95 nanometers to 105 nanometers (which is +1-5% of 100 nanometers), 90 to 110 nanometers (which is +/-10% of 100 nanometers), or 85 nanometers to 115 nanometers (which is +/-15% of 100 nanometers) depending on the embodiments.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023504251A JP2023535405A (ja) | 2020-07-22 | 2021-07-22 | 呼吸器疾患に関連する状態の処置および防止 |
| CN202180064648.3A CN116669708A (zh) | 2020-07-22 | 2021-07-22 | 呼吸系统疾病相关病症的治疗和预防 |
| EP21847219.9A EP4185272A4 (en) | 2020-07-22 | 2021-07-22 | Treatment and prevention of conditions associated with respiratory diseases |
| US18/017,659 US20230270845A1 (en) | 2020-07-22 | 2021-07-22 | Treatment and prevention of conditions associated with respiratory diseases |
| CA3186799A CA3186799A1 (en) | 2020-07-22 | 2021-07-22 | Treatment and prevention of conditions associated with respiratory diseases |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055165P | 2020-07-22 | 2020-07-22 | |
| US63/055,165 | 2020-07-22 | ||
| US202063060503P | 2020-08-03 | 2020-08-03 | |
| US63/060,503 | 2020-08-03 | ||
| US202063108980P | 2020-11-03 | 2020-11-03 | |
| US63/108,980 | 2020-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022020542A1 true WO2022020542A1 (en) | 2022-01-27 |
Family
ID=79729865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2021/042684 Ceased WO2022020542A1 (en) | 2020-07-22 | 2021-07-22 | Treatment and prevention of conditions associated with respiratory diseases |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230270845A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4185272A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023535405A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3186799A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022020542A1 (cg-RX-API-DMAC10.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114712304A (zh) * | 2022-04-18 | 2022-07-08 | 深圳大学 | 海藻酸钠基复合水凝胶的制备方法 |
| WO2023141328A1 (en) * | 2022-01-21 | 2023-07-27 | University Of Houston System | Intranasal vaccines and therapeutics for respiratory diseases |
| WO2025199149A1 (en) * | 2024-03-18 | 2025-09-25 | Cour Pharmaceuticals Development Company Inc. | Sting agonism for antigen specific tolerance |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025194158A1 (en) * | 2024-03-15 | 2025-09-18 | University Of Houston System | Mucosal vaccines against respiratory syncytial virus |
| CN120459057B (zh) * | 2025-06-06 | 2026-04-14 | 上海大学 | 一种单核细胞搭载型产氧脂质体及其制备方法和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017223085A2 (en) * | 2016-06-20 | 2017-12-28 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| KR20180106825A (ko) * | 2017-03-17 | 2018-10-01 | 주식회사 큐라티스 | 스팅 작용자를 포함하는 면역항원보강제 및 백신 조성물 |
| WO2019183578A1 (en) * | 2018-03-23 | 2019-09-26 | Codiak Biosciences, Inc. | Extracellular vesicles comprising sting-agonist |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
| KR102483033B1 (ko) * | 2016-05-16 | 2022-12-30 | 액세스 투 어드밴스드 헬스 인스티튜트 | 페길화된 리포솜 및 이의 용도 |
-
2021
- 2021-07-22 JP JP2023504251A patent/JP2023535405A/ja active Pending
- 2021-07-22 US US18/017,659 patent/US20230270845A1/en active Pending
- 2021-07-22 CA CA3186799A patent/CA3186799A1/en active Pending
- 2021-07-22 EP EP21847219.9A patent/EP4185272A4/en active Pending
- 2021-07-22 WO PCT/US2021/042684 patent/WO2022020542A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017223085A2 (en) * | 2016-06-20 | 2017-12-28 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| KR20180106825A (ko) * | 2017-03-17 | 2018-10-01 | 주식회사 큐라티스 | 스팅 작용자를 포함하는 면역항원보강제 및 백신 조성물 |
| WO2019183578A1 (en) * | 2018-03-23 | 2019-09-26 | Codiak Biosciences, Inc. | Extracellular vesicles comprising sting-agonist |
Non-Patent Citations (3)
| Title |
|---|
| NAKAMURA TAKASHI; MIYABE HIROKO; HYODO MAMORU; SATO YUSUKE; HAYAKAWA YOSHIHIRO; HARASHIMA HIDEYOSHI: "Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 216, 14 August 2015 (2015-08-14), AMSTERDAM, NL , pages 149 - 157, XP029276987, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2015.08.026 * |
| SANDEEP T. KOSHY, ALEXANDER S. CHEUNG, LUO GU, AMANDA R. GRAVELINE, DAVID J. MOONEY: "Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy", ADVANCED BIOSYSTEMS, vol. 1, no. 1-2, 1 February 2017 (2017-02-01), pages 1600013, XP055525816, ISSN: 2366-7478, DOI: 10.1002/adbi.201600013 * |
| See also references of EP4185272A4 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023141328A1 (en) * | 2022-01-21 | 2023-07-27 | University Of Houston System | Intranasal vaccines and therapeutics for respiratory diseases |
| CN114712304A (zh) * | 2022-04-18 | 2022-07-08 | 深圳大学 | 海藻酸钠基复合水凝胶的制备方法 |
| CN114712304B (zh) * | 2022-04-18 | 2024-03-12 | 深圳大学 | 海藻酸钠基复合水凝胶的制备方法 |
| WO2025199149A1 (en) * | 2024-03-18 | 2025-09-25 | Cour Pharmaceuticals Development Company Inc. | Sting agonism for antigen specific tolerance |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3186799A1 (en) | 2022-01-27 |
| US20230270845A1 (en) | 2023-08-31 |
| EP4185272A4 (en) | 2025-01-22 |
| EP4185272A1 (en) | 2023-05-31 |
| JP2023535405A (ja) | 2023-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230270845A1 (en) | Treatment and prevention of conditions associated with respiratory diseases | |
| An et al. | Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2 | |
| US20250127879A1 (en) | Newcastle disease viruses and uses thereof | |
| Park et al. | Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2 | |
| JP6596411B2 (ja) | ニューカッスル病ウイルス及びその使用 | |
| KR20160047570A (ko) | 약독화된 뉴캐슬병 바이러스를 특징으로 하는 조성물 및 신생물을 치료하기 위한 사용 방법 | |
| Wang et al. | IL-7 promotes mRNA vaccine-induced long-term immunity | |
| Hu et al. | Chimeric mRNA-based COVID-19 vaccine induces protective immunity against Omicron and Delta variants | |
| US20240115610A1 (en) | Genetically engineered diagnostic cells and antigen tests | |
| Giovannoni et al. | Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy | |
| US20250195638A1 (en) | Treatment and prevention of conditions associated with respiratory diseases | |
| Tang et al. | Mechanisms of superior respiratory IgA responses against SARS-CoV-2 after mucosal vaccination | |
| Wen et al. | A new mRNA antigen vaccine induces potent B and T cell responses and in vivo protection against SARS-CoV-2 | |
| US20230233674A1 (en) | Intranasal vaccines and therapeutics for respiratory diseases | |
| Slamanig | Development of an intranasal SARS-CoV-2 vaccine | |
| Chen et al. | Immunogenicity, Efficacy and Twelve-Month Storage Stability Studies of a Lyophilized Rabies mRNA Vaccine. Vaccines 2025, 13, 743 | |
| Davis-Porada | Human Immune Memory to COVID-19 mRNA Vaccines | |
| Kim et al. | Development of Nanobody-Expressing Nanosomes for Neutralization of Influenza Virus | |
| WO2024182737A1 (en) | Oncolytic viruses to treat brain cancer | |
| HK40122702A (en) | Intranasal vaccines and therapeutics for respiratory diseases | |
| Wu | Memory CD8 T Cell Reactivation During Secondary Influenza Virus Infection | |
| Turner | Temporal and spatial distribution of antigen following respiratory viral infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21847219 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2023504251 Country of ref document: JP Kind code of ref document: A Ref document number: 3186799 Country of ref document: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2021847219 Country of ref document: EP Effective date: 20230222 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202180064648.3 Country of ref document: CN |